BIOMARIN PHARMACEUTICAL INC Insider Trading for March 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOMARIN PHARMACEUTICAL INC for March 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 31 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.15 | 3,890 | 346,794 | 51,532 | 55.4 K to 51.5 K (-7.02 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 87.42 | 36,280 | 3,171,598 | 36,820 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 11,220 | 0 | 84,949 | 73.7 K to 84.9 K (+15.22 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 87.42 | 144,050 | 12,592,851 | 144,050 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 44,520 | 0 | 235,194 | 190.7 K to 235.2 K (+23.35 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 87.42 | 7,740 | 676,631 | 7,740 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 4,790 | 0 | 18,080 | 13.3 K to 18.1 K (+36.04 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 87.42 | 64,030 | 5,597,503 | 64,030 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 19,790 | 0 | 140,192 | 120.4 K to 140.2 K (+16.44 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,200 | 0 | 55,422 | 43.2 K to 55.4 K (+28.23 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,200 | 0 | 26,671 | 14.5 K to 26.7 K (+84.31 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 87.42 | 38,420 | 3,358,676 | 38,420 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 11,870 | 0 | 147,491 | 135.6 K to 147.5 K (+8.75 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 92.50 | 3,288 | 304,140 | 43,222 | 46.5 K to 43.2 K (-7.07 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 92.50 | 5,116 | 473,230 | 120,402 | 125.5 K to 120.4 K (-4.08 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 92.50 | 3,289 | 304,233 | 135,621 | 138.9 K to 135.6 K (-2.37 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 90.96 | 376 | 34,201 | 13,290 | 13.7 K to 13.3 K (-2.75 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 92.50 | 336 | 31,080 | 13,666 | 14 K to 13.7 K (-2.40 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 91.96 | 2,238 | 205,806 | 73,729 | 76 K to 73.7 K (-2.95 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 92.50 | 2,995 | 277,038 | 75,967 | 79 K to 76 K (-3.79 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 91.96 | 1,989 | 182,908 | 14,471 | 16.5 K to 14.5 K (-12.08 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 92.50 | 4,301 | 397,843 | 16,460 | 20.8 K to 16.5 K (-20.72 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 57,423 | |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 62,423 | |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.96 | 5,000 | 459,800 | 190,674 | 195.7 K to 190.7 K (-2.56 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 71.33 | 5,000 | 356,650 | 195,674 | 190.7 K to 195.7 K (+2.62 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 92.50 | 15,690 | 1,451,325 | 190,674 | 206.4 K to 190.7 K (-7.60 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.42 | 5,000 | 457,100 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 67,423 | |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 92.68 | 5,000 | 463,400 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 72,423 | |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 6,000 | 103,980 | 77,423 | |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.09 | 5,000 | 455,450 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.18 | 6,000 | 541,080 | 206,364 | 212.4 K to 206.4 K (-2.83 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 6,000 | 103,980 | 212,364 | 206.4 K to 212.4 K (+2.91 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.56 | 5,000 | 452,800 | 46,510 | 51.5 K to 46.5 K (-9.71 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 93.32 | 2,303 | 214,916 | 20,761 | 23.1 K to 20.8 K (-9.99 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 93.32 | 1,498 | 139,793 | 78,962 | 80.5 K to 79 K (-1.86 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 93.95 | 1,749 | 164,319 | 51,510 | 53.3 K to 51.5 K (-3.28 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 93.95 | 1,749 | 164,319 | 138,910 | 140.7 K to 138.9 K (-1.24 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 93.95 | 1,596 | 149,944 | 80,460 | 82.1 K to 80.5 K (-1.95 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 93.95 | 2,283 | 214,488 | 23,064 | 25.3 K to 23.1 K (-9.01 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 93.95 | 8,989 | 844,517 | 206,364 | 215.4 K to 206.4 K (-4.17 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 93.95 | 2,924 | 274,710 | 125,518 | 128.4 K to 125.5 K (-2.28 %) |